Market Research Logo

Bone Fracture - Pipeline Review, H2 2015

Bone Fracture - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Bone Fracture - Pipeline Review, H2 2015’, provides an overview of the Bone Fracture’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bone Fracture, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Fracture and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Bone Fracture
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Bone Fracture and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Bone Fracture products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Bone Fracture pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Bone Fracture
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Bone Fracture pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Bone Fracture Overview
Therapeutics Development
Pipeline Products for Bone Fracture - Overview
Pipeline Products for Bone Fracture - Comparative Analysis
Bone Fracture - Therapeutics under Development by Companies
Bone Fracture - Therapeutics under Investigation by Universities/Institutes
Bone Fracture - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Bone Fracture - Products under Development by Companies
Bone Fracture - Products under Investigation by Universities/Institutes
Bone Fracture - Companies Involved in Therapeutics Development
Arcarios BV
AstraZeneca Plc
Biogenomics Limited
Biopharm GmbH
Bone Therapeutics SA
Juventas Therapeutics, Inc.
Kaken Pharmaceutical Co., Ltd.
Kolon Life Science, Inc.
Kuros Biosurgery AG
Novartis AG
OrgaNext Research BV
TissueGene, Inc.
Viking Therapeutics, Inc.
Bone Fracture - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(nandrolone decanoate + cholecalciferol) - Drug Profile Product Description
Mechanism of Action
R&D Progress
ALLOB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZD-2858 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bimagrumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
denosumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dibotermin alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs to Modulate Bone Morphogenetic Protein for Osteoarthritis and Fracture - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Bone Fracture - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JVS-200 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
K-436 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KCB-1B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KLS-Bfr - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KUR-111 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KUR-113 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LWnt-3a - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein for Degenerative Disc Disease, Bone Fracture, Parkinson's Disease and Erectile Dysfunction - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein to Activate TNF alfa for Fracture Repair - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Immunology, Musculoskeletal and Metabolic Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stromal Cell Therapy for Fracture Repair - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptide for Osteoporosis and Bone Fracture - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TG-B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VK-5211 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bone Fracture - Recent Pipeline Updates
Bone Fracture - Dormant Projects
Bone Fracture - Discontinued Products
Bone Fracture - Product Development Milestones
Featured News & Press Releases
Nov 03, 2015: Viking Therapeutics Initiates Phase 2 Trial of VK5211 in Patients Recovering From Hip Fracture
Oct 20, 2015: Viking Therapeutics Completes Safety, Tolerability and Pharmacokinetic Study of VK5211, a Selective Androgen Receptor Modulator, in Healthy Elderly Subjects
Oct 09, 2015: Kuros Presents Results of Phase IIB Study with KUR-111 at the 2015 Orthopaedic Trauma Association Annual Meeting
Sep 01, 2015: Viking Therapeutics Initiates Clinical Trial for VK5211, a Selective Androgen Receptor Modulator, for Acute Hip Fracture
Jul 14, 2015: Viking Therapeutics Submits Investigational New Drug (IND) Application for VK5211, a Selective Androgen Receptor Modulator (SARM), in Acute Hip Fracture
Aug 29, 2013: Researcher Awarded $5 Million to Advance Future Stem Cell Treatments for Segmental Bone Fractures
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Bone Fracture, H2 2015
Number of Products under Development for Bone Fracture - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Bone Fracture - Pipeline by Arcarios BV, H2 2015
Bone Fracture - Pipeline by AstraZeneca Plc, H2 2015
Bone Fracture - Pipeline by Biogenomics Limited, H2 2015
Bone Fracture - Pipeline by Biopharm GmbH, H2 2015
Bone Fracture - Pipeline by Bone Therapeutics SA, H2 2015
Bone Fracture - Pipeline by Juventas Therapeutics, Inc., H2 2015
Bone Fracture - Pipeline by Kaken Pharmaceutical Co., Ltd., H2 2015
Bone Fracture - Pipeline by Kolon Life Science, Inc., H2 2015
Bone Fracture - Pipeline by Kuros Biosurgery AG, H2 2015
Bone Fracture - Pipeline by Novartis AG, H2 2015
Bone Fracture - Pipeline by OrgaNext Research BV, H2 2015
Bone Fracture - Pipeline by TissueGene, Inc., H2 2015
Bone Fracture - Pipeline by Viking Therapeutics, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Bone Fracture Therapeutics - Recent Pipeline Updates, H2 2015
Bone Fracture - Dormant Projects, H2 2015
Bone Fracture - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Bone Fracture, H2 2015
Number of Products under Development for Bone Fracture - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report